Markus Glatt

TL;DR: The induction of bone cancer in the rat by the syngeneic MRMT‐1 mammary tumour cell line provides a valid pre‐clinical model for pain associated with bone metastases and suggests a reasonable time window for evaluation of anti‐nociceptive agents between day 14 and 20 after cancer cell inoculation in this model.

TL;DR: GP130 is essential for normal bone growth and trabecular bone mass, with balanced regulation depending on selective activation of STAT1/3 and SHP2/ras/MAPK, respectively, the latter pathway can directly inhibit osteoclastogenesis in vivo.

TL;DR: A novel class of Src inhibitors, substituted 5,7-diphenyl-pyrrolo[2,3-d]pyrimidines, is described and characterized and partly prevented bone loss and microarchitectural changes in young ovariectomized rats, showing that the protective effect on bone was exerted via the inhibition of bone resorption.

TL;DR: Single doses of ZA strikingly reduced focal bone erosions and juxtaarticular trabecular bone loss, although synovitis was mildly exacerbated, and targeting osteoclasts with ZA may be an effective strategy for preventing structural joint damage in rheumatoid arthritis.

TL;DR: It is concluded that zoledronic acid, in addition to, or independent from, its anti‐metastatic and bone preserving therapeutic effects, is an anti‐nociceptive agent in a rat model of metastatic cancer pain.